Product Description
TL011, anti CD20, for the treatment of rheumatoid arthritis (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT01123070)
Mechanisms of Action: CD20 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Arthritis, Rheumatoid
Phase 1: Arthritis, Rheumatoid|Diffuse Large B-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NHL-TL011-102 | P1 |
Completed |
Diffuse Large B-Cell Lymphoma |
2013-07-01 |
|
| ALTO | P3 |
Terminated |
Arthritis, Rheumatoid |
2012-08-01 |
|
| RA-TL011-101 | P1 |
Completed |
Arthritis, Rheumatoid |
2012-04-23 |